Developer docs
API playgroundTry for free, no card

Search company profiles

Celyad

Full company profile

uuid00044gn

Namestring
Celyad
Legal namestring
Celyad Oncology SA
Websiteurl
celyad.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Celyad Oncology SA (formerly Celyad SA) is a Belgian clinical-stage biotechnology company, founded in 2007 and headquartered in Mont-Saint-Guibert, Belgium, that historically developed autologous and allogeneic CAR-T cell therapies for hematologic malignancies and solid tumors. Its core technology platform combined an NKG2D-based chimeric antigen receptor with a proprietary short hairpin RNA (shRNA) multiplexing system designed to enhance CAR-T persistence, safety, and allogeneic compatibility. The company previously advanced candidates including CYAD-01 (autologous NKG2D CAR-T), CYAD-02 (TIM-3 knock-out variant), CYAD-101 (allogeneic NKG2D CAR-T in colorectal cancer), CYAD-211 (BCMA-targeting allogeneic CAR-T), and CYAD-203 (IL-18-armored candidate).

Following strategic reviews in 2022 and 2024, Celyad discontinued all clinical development and pivoted to a "Celyad 2.0" IP-monetization model. The business model now consists of (i) divestiture of operating assets (GMP manufacturing sold to Cellistic for €6M in 2022; research facility sold for €3M in 2025; C-CATHez catheter business sold to CellProthera for up to €5M plus royalties in 2026), and (ii) licensing and royalty arrangements derived from its residual patent estate (12+ US patents covering NKG2D, shRNA, and cell-therapy manufacturing). The company has no product revenue, a minimal core team, and a going-concern qualification issued by auditor BDO. Cash and equivalents stood at €1.7M at December 2025, with operations funded through small private placements primarily from Fortress Investment Group affiliates, which now control 60.52% of shares and 68.75% of voting rights. Shares trade on Euronext Brussels and Euronext Paris following a July 2023 delisting from Nasdaq.

Short descriptiontext

Celyad Oncology SA is a Belgian former clinical-stage CAR-T cell therapy company that has discontinued all R&D and now operates as an IP-monetization vehicle, divesting assets (Cellistic, CellProthera) and licensing its residual NKG2D and shRNA patent estate to generate cash.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMont-saint-guibert, Belgium
HQ citystring
Mont-saint-guibert
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotechnology research, cell therapy development, clinical stage therapeutics, oncology drug development, biopharmaceutical pipeline
Product category
Biotechnology
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1IP Licensing and Partnership Agreements
TypeLicensing Royalties
Description

The company generates no current revenue but is actively pursuing out-licensing deals for its CAR T-cell technology platforms and intellectual property portfolio. Discussions with potential partners for selected out-licensing of technologies are ongoing.

celyad.com
2Asset Sales
TypeTransaction Fee
Description

Sale of non-core assets including the research facility (€3 million) and C-CATHez catheter technology (up to €5 million in milestone-based payments plus royalties). These are one-time transactions to extend cash runway.

celyad.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1C-CATHez
Description

Transendocardial catheter technology for cardiac cell therapy delivery

celyad.com
+2 more records
Core offering1 text field

No core offering details are evidenced in the provided input beyond the company name "Celyad".

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • shRNA multiplexing enables simultaneous knockdown of up to four target genes
+3 more records
Product overview1 text field

Celyad Oncology is a biotechnology company that has developed proprietary technology platforms for CAR T-cell therapies. The company's core offerings include its shRNA multiplexing technology platform enabling non-gene edited allogeneic CAR T development, and its NKG2D-based CAR T-cell platform for multi-specific targeting. Historically, the company developed several clinical candidates including CYAD-01, CYAD-101, CYAD-211, CYAD-02, and CYAD-203, all of which have been discontinued. Celyad has also sold its C-CATHez transendocardial catheter to CellProthera. As of 2025, the company has discontinued R&D activities and is focusing on IP management and out-licensing of its technology platforms.

Product and service1 record
1No products or services are evidenced in the provided input.
CategoryNo category is evidenced in the provided input.
Description

No product or service description is evidenced in the provided input.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-12
Description

CellProthera acquired full intellectual property rights to Celyad Oncology's C-CATHez transendocardial catheter for up to €5 million in milestone-based payments plus future royalties on net sales. The catheter will be used for targeted delivery of stem cells in CellProthera's Phase 3 clinical trials for cardiac tissue regeneration.

2Cellistic
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-20
Description

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, acquired Celyad Oncology's GMP grade cell therapy manufacturing business unit including the facility and personnel for €6 million. The 11,000 square foot facility was transferred and more than 30 manufacturing personnel joined Cellistic.

celyad.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-02-28
Description

MSD collaborated with Celyad Oncology on the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial evaluating TIM-based allogeneic NKG2D CAR T-cell therapy with KEYTRUDA (pembrolizumab) in patients with metastatic colorectal cancer. The trial was placed on clinical hold following two fatalities.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Allogene is a leading clinical-stage allogeneic CAR T-cell therapy company developing off-the-shelf cell therapies for hematological malignancies and solid tumors. It is the most direct allogeneic CAR T platform peer to Celyad's NKG2D and shRNA-based allogeneic programs.

TypeDirect peer
Description

Cellectis develops gene-edited allogeneic CAR T-cell therapies (UCART platform) using TALEN-based gene editing. It is a direct peer to Celyad's allogeneic platform efforts, with comparable engineering approaches to address GvHD and host-versus-graft rejection.

TypeDirect peer
Description

Precision BioSciences develops allogeneic CAR T-cell therapies using its proprietary ARCUS gene editing platform. Highly comparable to Celyad's gene-modification approach to allogeneic CAR T, and notably was co-founded by Celyad's current CEO Matt Kane.

TypeDirect peer
Description

Caribou Biosciences develops allogeneic CAR T-cell therapies using CRISPR-based gene editing (Cas12a chRDNA platform). Direct peer in the allogeneic CAR T space with comparable IP-licensing and platform-partnership business model dynamics.

TypeBroad incumbent
Description

CRISPR Therapeutics is a leading gene editing company developing CRISPR/Cas9-based therapies including allogeneic CAR T candidates (e.g., CTX112). As a much larger and broader platform player, it represents a well-funded incumbent competing for the same allogeneic CAR T market.

TypeDirect peer
Description

Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors. Comparable to Celyad's autologous and allogeneic cell therapy approach for oncology, with overlapping scientific leadership in receptor-engineered cell therapies.

TypeDirect peer
Description

Iovance is a leading cell therapy company commercializing tumor-infiltrating lymphocyte (TIL) therapies. Peer in the broader cell therapy oncology space, illustrating what successful commercialization of a cell therapy platform looks like — a benchmark Celyad is no longer pursuing.

TypeDirect peer
Description

Atara develops allogeneic T-cell and CAR T immunotherapies for solid tumors and hematologic malignancies. Direct peer in the allogeneic T-cell platform space, and a useful comparable for the strategic challenges of monetizing an allogeneic cell therapy platform.

9Tmunity Therapeutics
TypeEmerging player
Description

Tmunity is a clinical-stage cell therapy company developing next-generation engineered T-cell therapies including CAR T programs. It is an emerging player with overlapping technology and indication focus relative to Celyad's NKG2D platform.

TypeOthers
Description

Celdara Medical is a biotech studio and the originating licensor of certain allogeneic cell therapy IP that Celyad in-licensed from Dartmouth. It is a relevant ecosystem participant given its contingent consideration arrangement and the in-licensed IP estate underpinning Celyad's platforms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celyad

Biotechnologycelyad.com

Celyad Oncology SA is a Belgian former clinical-stage CAR-T cell therapy company that has discontinued all R&D and now operates as an IP-monetization vehicle, divesting assets (Cellistic, CellProthera) and licensing its residual NKG2D and shRNA patent estate to generate cash.

What Celyad does

Celyad Oncology SA (formerly Celyad SA) is a Belgian clinical-stage biotechnology company, founded in 2007 and headquartered in Mont-Saint-Guibert, Belgium, that historically developed autologous and allogeneic CAR-T cell therapies for hematologic malignancies and solid tumors. Its core technology platform combined an NKG2D-based chimeric antigen receptor with a proprietary short hairpin RNA (shRNA) multiplexing system designed to enhance CAR-T persistence, safety, and allogeneic compatibility. The company previously advanced candidates including CYAD-01 (autologous NKG2D CAR-T), CYAD-02 (TIM-3 knock-out variant), CYAD-101 (allogeneic NKG2D CAR-T in colorectal cancer), CYAD-211 (BCMA-targeting allogeneic CAR-T), and CYAD-203 (IL-18-armored candidate).

Following strategic reviews in 2022 and 2024, Celyad discontinued all clinical development and pivoted to a "Celyad 2.0" IP-monetization model. The business model now consists of (i) divestiture of operating assets (GMP manufacturing sold to Cellistic for €6M in 2022; research facility sold for €3M in 2025; C-CATHez catheter business sold to CellProthera for up to €5M plus royalties in 2026), and (ii) licensing and royalty arrangements derived from its residual patent estate (12+ US patents covering NKG2D, shRNA, and cell-therapy manufacturing). The company has no product revenue, a minimal core team, and a going-concern qualification issued by auditor BDO. Cash and equivalents stood at €1.7M at December 2025, with operations funded through small private placements primarily from Fortress Investment Group affiliates, which now control 60.52% of shares and 68.75% of voting rights. Shares trade on Euronext Brussels and Euronext Paris following a July 2023 delisting from Nasdaq.

Celyad firmographics

Firmographics
Name
Celyad
Legal name
Celyad Oncology SA
Website
https://celyad.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Celyad Oncology SA is a Belgian former clinical-stage CAR-T cell therapy company that has discontinued all R&D and now operates as an IP-monetization vehicle, divesting assets (Cellistic, CellProthera) and licensing its residual NKG2D and shRNA patent estate to generate cash.
Ownership category
akta.pro rank

Where Celyad is headquartered

Location

Headquarters

HQ city
Mont-saint-guibert
HQ country
Belgium
HQ region
Europe

Offices1 record

Markets served

Celyad business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. IP Licensing and Partnership Agreements: The company generates no current revenue but is actively pursuing out-licensing deals for its CAR T-cell technology platforms and intellectual property portfolio. Discussions with potential partners for selected out-licensing of technologies are ongoing.
  2. Asset Sales: Sale of non-core assets including the research facility (€3 million) and C-CATHez catheter technology (up to €5 million in milestone-based payments plus royalties). These are one-time transactions to extend cash runway.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Celyad product offering

Product offering

Core offering

No core offering details are evidenced in the provided input beyond the company name "Celyad".

Product overview

Celyad Oncology is a biotechnology company that has developed proprietary technology platforms for CAR T-cell therapies. The company's core offerings include its shRNA multiplexing technology platform enabling non-gene edited allogeneic CAR T development, and its NKG2D-based CAR T-cell platform for multi-specific targeting. Historically, the company developed several clinical candidates including CYAD-01, CYAD-101, CYAD-211, CYAD-02, and CYAD-203, all of which have been discontinued. Celyad has also sold its C-CATHez transendocardial catheter to CellProthera. As of 2025, the company has discontinued R&D activities and is focusing on IP management and out-licensing of its technology platforms.

Differentiator

Problem solved

Functional benefit

Brands

  • C-CATHez: Transendocardial catheter technology for cardiac cell therapy delivery
  • shRNA platform
  • NKG2D-based CAR T-cell platform

Products and services

  • No products or services are evidenced in the provided input. No product or service description is evidenced in the provided input.

Quantifiable outcome

  • shRNA multiplexing enables simultaneous knockdown of up to four target genes
  • +3 more outcomes

Companies that use Celyad

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Celyad technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Celyad partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • CellProtheracoreStrategic or Co-development Partner · 12 February 2026CellProthera acquired full intellectual property rights to Celyad Oncology's C-CATHez transendocardial catheter for up to €5 million in milestone-based payments plus future royalties on net sales. The catheter will be used for targeted delivery of stem cells in CellProthera's Phase 3 clinical trials for cardiac tissue regeneration.
  • CellisticcoreStrategic or Co-development Partner · 20 September 2022Cellistic, the cell therapy development and manufacturing business of Ncardia BV, acquired Celyad Oncology's GMP grade cell therapy manufacturing business unit including the facility and personnel for €6 million. The 11,000 square foot facility was transferred and more than 30 manufacturing personnel joined Cellistic.
  • MSD (Merck & Co.)minorStrategic or Co-development Partner · 28 February 2022MSD collaborated with Celyad Oncology on the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial evaluating TIM-based allogeneic NKG2D CAR T-cell therapy with KEYTRUDA (pembrolizumab) in patients with metastatic colorectal cancer. The trial was placed on clinical hold following two fatalities.

Scale indicators8 records

Recent moves9 records

Expansion highlights2 records

Celyad competitors and assessment

Company assessment

Direct peers

  • Allogene Therapeutics: Allogene is a leading clinical-stage allogeneic CAR T-cell therapy company developing off-the-shelf cell therapies for hematological malignancies and solid tumors. It is the most direct allogeneic CAR T platform peer to Celyad's NKG2D and shRNA-based allogeneic programs.
  • Cellectis: Cellectis develops gene-edited allogeneic CAR T-cell therapies (UCART platform) using TALEN-based gene editing. It is a direct peer to Celyad's allogeneic platform efforts, with comparable engineering approaches to address GvHD and host-versus-graft rejection.
  • Precision BioSciences: Precision BioSciences develops allogeneic CAR T-cell therapies using its proprietary ARCUS gene editing platform. Highly comparable to Celyad's gene-modification approach to allogeneic CAR T, and notably was co-founded by Celyad's current CEO Matt Kane.
  • Caribou Biosciences: Caribou Biosciences develops allogeneic CAR T-cell therapies using CRISPR-based gene editing (Cas12a chRDNA platform). Direct peer in the allogeneic CAR T space with comparable IP-licensing and platform-partnership business model dynamics.
  • Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors. Comparable to Celyad's autologous and allogeneic cell therapy approach for oncology, with overlapping scientific leadership in receptor-engineered cell therapies.
  • Iovance Biotherapeutics: Iovance is a leading cell therapy company commercializing tumor-infiltrating lymphocyte (TIL) therapies. Peer in the broader cell therapy oncology space, illustrating what successful commercialization of a cell therapy platform looks like — a benchmark Celyad is no longer pursuing.
  • Atara Biotherapeutics: Atara develops allogeneic T-cell and CAR T immunotherapies for solid tumors and hematologic malignancies. Direct peer in the allogeneic T-cell platform space, and a useful comparable for the strategic challenges of monetizing an allogeneic cell therapy platform.

Broad incumbents

  • CRISPR Therapeutics: CRISPR Therapeutics is a leading gene editing company developing CRISPR/Cas9-based therapies including allogeneic CAR T candidates (e.g., CTX112). As a much larger and broader platform player, it represents a well-funded incumbent competing for the same allogeneic CAR T market.

Emerging players

  • Tmunity Therapeutics: Tmunity is a clinical-stage cell therapy company developing next-generation engineered T-cell therapies including CAR T programs. It is an emerging player with overlapping technology and indication focus relative to Celyad's NKG2D platform.

Others

  • Celdara Medical: Celdara Medical is a biotech studio and the originating licensor of certain allogeneic cell therapy IP that Celyad in-licensed from Dartmouth. It is a relevant ecosystem participant given its contingent consideration arrangement and the in-licensed IP estate underpinning Celyad's platforms.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks7 records

Key highlights6 records

Customer concentration

Celyad social profiles

Digital presence

Celyad financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celyad leadership team

Management profile

Number of profiles

Profiles1 record

Celyad funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celyad M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celyad

What does Celyad do?

No core offering details are evidenced in the provided input beyond the company name "Celyad".

Is Celyad a public or private company?

Celyad is a public company. It is classified as unknown and is currently operating.

When was Celyad founded?

Celyad was founded in 2007. It employs 11 to 50 people.

Where is Celyad based?

Celyad is headquartered in Mont-saint-guibert, Belgium, in the Europe region.

How does Celyad make money?

Two revenue lines are on record. IP Licensing and Partnership Agreements are the primary driver. The others are asset Sales.

Who are Celyad's main competitors?

Direct peers on record are Allogene Therapeutics, Cellectis, Precision BioSciences, Caribou Biosciences, Adaptimmune Therapeutics, Iovance Biotherapeutics and Atara Biotherapeutics. CRISPR Therapeutics is listed as a broad incumbent. Tmunity Therapeutics is listed as an emerging player. Celdara Medical is listed as an others.

Does Celyad have an API?

No public API is recorded for Celyad.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogCelyad Oncology Reports First Half Year 2026 ResultsCelyad Oncology reported a net loss of €1.2 million for the first half of 2026, down from €3.7 million in the same period of 2025. The company's cash position stood at €0.1 million as of June 30, 2026, and it projects existing cash will fund operations through 2027.Stock TitanCelyad Oncology H1 2026 net loss narrows to €1.2MCelyad Oncology reported a net loss of €1.2 million for the first half of 2026, down from €3.7 million in the same period of 2025. The company's cash position stood at €0.1 million as of June 30, 2026, and it projects existing funds will cover estimated spending into 2027.The future of tradingCelyad Oncology H1 FY26 net loss narrows to €1.2 million; operating loss narrows to €1.2 millionCelyad Oncology reported a net loss of €1.2 million for the first half of fiscal 2026, narrowing from €3.7 million a year earlier. Operating loss also narrowed to €1.2 million, with employee benefit expense falling 71.43% to €0.4 million. Cash and cash equivalents stood at €0.1 million at June 30, and a €0.5 million capital increase on July 16 strengthened liquidity.Stock TitanCelyad Oncology Issues 2.5M Shares, 47.3M TotalCelyad Oncology announced the issuance of 2,500,000 new shares to an affiliate of Fortress Investment Group on July 16, 2026, increasing the company's total shares to 47,261,905 and share capital to 10,437,000 EUR. The disclosure, made in accordance with Belgian securities law (Article 15 of the Law of 2 May 2007), also reports 3,487,923 attributed warrants that could create additional diluted shares. This is a routine regulatory filing regarding major share participations for the Euronext-listed biotechnology company headquartered in Mont-Saint-Guibert, Belgium.Business Wire BlogCelyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)Celyad Oncology announced the issuance of 2,500,000 new shares to an affiliate of Fortress Investment Group on July 16, 2026, increasing the company's share capital to €10,437,000.00 represented by 47,261,905 shares. The disclosure is made in compliance with Article 15 of the Belgian Law of May 2, 2007 regarding major share participations in publicly traded companies. Following this capital increase, total voting rights stand at 74,883,166, with diluted shares reaching 50,749,828.Investing.comCelyad Oncology raises €500,000 from Fortress Investment Group By Investing.comCelyad Oncology SA entered into a subscription agreement with Fortress Investment Group for a €500,000 private placement financing, issuing 2,500,000 ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price. Following the issuance expected to close on or around July 15, Fortress Investment Group will hold approximately 60.52% of the company's outstanding shares and 68.75% of voting rights. The financing will extend Celyad's cash runway from Q3 2026 to mid-Q2 2027 for working capital and general corporate purposes.Investing.comCelyad Oncology raises €500,000 from Fortress Investment Group By Investing.comCelyad Oncology SA announced it entered into a subscription agreement for a private placement financing with Fortress Investment Group LLC, raising €500,000 through the issuance of 2,500,000 new ordinary shares at €0.20 per share. Following the issuance, Fortress will hold approximately 60.52% of the company's outstanding shares and 68.75% of voting rights. The financing is expected to close on or around July 15, 2026, and will extend the company's cash runway from Q3 2026 to mid Q2 2027.Stock TitanCelyad Oncology Enters €500K Private PlacementCelyad Oncology SA announced a €500,000 private placement financing with Fortress Investment Group LLC, under which Fortress will subscribe to 2,500,000 newly issued shares at €0.20 per share, representing a 15% discount to the 10-day VWAP on Euronext Brussels. Following the transaction expected to close around July 15, 2026, Fortress will hold approximately 60.52% of outstanding shares and 68.75% of voting rights, making it a related-party transaction under Belgian law. The proceeds will extend the company's cash runway from Q3 2026 to mid Q2 2027, providing additional time to strengthen its balance sheet.Business Wire BlogCelyad Oncology Announces €500,000 Private PlacementCelyad Oncology has entered into a subscription agreement with Fortress Investment Group for a €500,000 private placement financing, issuing 2,500,000 shares at €0.20 per share representing a 15% discount. Upon closing, expected around July 15, 2026, Fortress will hold approximately 60.52% of outstanding shares and 68.75% of voting rights. The proceeds will extend the company's cash runway from Q3 2026 to mid Q2 2027 for working capital and general corporate purposes.Business Wire BlogCelyad Oncology Reports Full Year 2025 Financial Results and Business HighlightsCelyad Oncology announced its full year 2025 financial results, reporting a net profit of €0.8 million compared to a net loss of €5.8 million in 2024, and disclosed its decision to discontinue R&D activities and sell its research facility. The company cited its cash position as insufficient to cover expenses beyond the next 12 months but highlighted the sale of its research facility for €3 million and a shareholder proposal to continue its activities in the upcoming shareholders' meeting.